EcoDrugPlus

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Alpha 4

Ensembl ID : ENSPEMG00000006928
Gene Symbol: GABRA4
1 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Gamma 3

Ensembl ID : ENSPEMG00000019431
Gene Symbol: GABRG3
1 Cross references
255 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSPEMG00000014107
Gene Symbol: GABBR2
1 Cross references
241 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha1 Subunit

Ensembl ID : ENSPEMG00000026750
Gene Symbol: GABRA1
3 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha2 Subunit

Ensembl ID : ENSPEMG00000023011
Gene Symbol: GABRA2
3 Cross references
253 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha5 Subunit

Ensembl ID : ENSPEMG00000019839
Gene Symbol: GABRA5
3 Cross references
262 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha6 Subunit

Ensembl ID : ENSPEMG00000000050
Gene Symbol: GABRA6
3 Cross references
195 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Beta1 Subunit

Ensembl ID : ENSPEMG00000022393
Gene Symbol: GABRB1
3 Cross references
102 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Beta2 Subunit

Ensembl ID : ENSPEMG00000017451
Gene Symbol: GABRB2
3 Cross references
275 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Beta3 Subunit

Ensembl ID : ENSPEMG00000023767
Gene Symbol: GABRB3
3 Cross references
263 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Delta Subunit

Ensembl ID : ENSPEMG00000018688
Gene Symbol: GABRD
3 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Gamma1 Subunit

Ensembl ID : ENSPEMG00000013424
Gene Symbol: GABRG1
3 Cross references
188 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).